2-Azabicyclo[3.1.0]hexan-3-one NIK Inhibitors for NF-kB Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, fibrotic conditions, and inflammatory diseases are limited in effectively inhibiting the NF-kB signaling pathway, which is often over-activated in these conditions, leading to undesired proliferation and inflammation.
Innovation Solution
Development of 4-alkynyl-4-hydroxy-2-azabicyclo[3.1.0]hexan-3-one compounds that act as inhibitors of NF-kB-inducing kinase (NIK), disrupting the NF-kB signaling pathway to treat diseases mediated by NIK kinase, such as cancer and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for cancer and inflammatory diseases, then existing therapy options are available, but the NF-kB signaling pathway remains over-activated leading to undesired proliferation and inflammation
Solution Approach 1:
The patent extracts and targets the specific kinase (NIK) that initiates the NF-kB signaling pathway. By developing compounds that selectively inhibit NIK kinase activity, the invention removes the root cause of pathway over-activation rather than treating downstream effects, thereby resolving the contradiction between maintaining therapy availability and achieving effective pathway inhibition.
Solution Approach 2:
The invention changes the biochemical parameter of NIK kinase activity through the development of specific inhibitor compounds. By modifying the kinetic parameters of NIK enzyme activity using structurally diverse compounds with varying potencies, the patent achieves effective NF-kB pathway inhibition while maintaining selective targeting, thus resolving the contradiction between therapy effectiveness and pathway over-activation.
2Reliability
If NIK kinase is inhibited to stop cancer cell proliferation, then therapeutic benefit is achieved, but the complexity of identifying and developing specific NIK inhibitors increases
Solution Approach 1:
The patent segments the NF-kB signaling pathway into its upstream initiator (NIK kinase) and downstream effectors. By focusing inhibition efforts specifically on NIK rather than targeting the entire pathway or downstream components, the invention simplifies the therapeutic approach while maintaining effectiveness against cancer cell proliferation, thus resolving the contradiction between therapeutic benefit and development complexity.
Solution Approach 2:
The patent uses NIK kinase as an intermediary target between the initial pathological stimulus and the harmful downstream effects (uncontrolled proliferation). By inhibiting NIK, the invention creates a therapeutic mediator that blocks signal transmission through the NF-kB pathway, achieving cancer cell proliferation control while providing a clear, targeted development pathway that reduces overall complexity.
Data Source
AI summary
The invention relates to compounds of formula (I):wherein Q, A1, A2, A3, A5, A6, A7, A8, R4a, R4b and R5 are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.